BME treatment suppressed the expression of the immune checkpoint gene PDCD1/PD1 and the proinflammatory genes IL1b, IL23a, and s100a9, which were reported to have elevated expression during oral cancer development. Here, PDCD1 is linked to lip and oral cavity carcinoma.